Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Dare Bioscience, Inc.CERU · Entity 7799 | Director | April 03, 2017 | April 05, 2017 |
| INCYTE CORPINCY · Entity 3182 | Director | May 26, 2020 | May 28, 2020 |
| MADRIGAL PHARMACEUTICALS, INC.MDGL · Entity 3441 | Director | January 09, 2026 | January 13, 2026 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Director | June 09, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Dare Bioscience, Inc.
Report date April 03, 2017 · Filed April 05, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,819 |
Reported balance
After 2017-04-03 transaction · row 1
1 source rowRow 1 · 2017-04-03 · Grant · Acquired 10,273 · Balance 18,819 F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the first fiscal quarter of 2017 divided by $0.73, the closing price of the company's common stock on the NASDAQ Global Market on April 3, 2017.
INCYTE CORP
Report date May 26, 2020 · Filed May 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 256,813 |
Reported balance
After 2020-05-26 transaction · row 1
1 source rowRow 1 · 2020-05-26 · Grant · Acquired 1,282 · Balance 256,813 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $98.68 · Expires 2030-05-25 | Direct | 10,514 |
Reported balance
After 2020-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-05-26 · Grant · Acquired 10,514 · Balance 10,514 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
| Common StockSEC Table I · non-derivative | IndirectBy Grat | 15,000 |
Reported balance
Holding disclosure · report date 2020-05-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 15,000 F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Shares were previously reported as directly beneficially owned but were contributed to a grantor retained annuity trust (GRAT) on April 3, 2019.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
MADRIGAL PHARMACEUTICALS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 187,164 |
Ending reported balance
After 2026-01-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-09 · Exercise / conversion · Acquired 280 · Balance 187,444 Row 2 · 2026-01-09 · Sale · Disposed 280 · Balance 187,164 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.80 · Expires 2027-03-02 | Direct | 0 |
Reported balance
After 2026-01-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-09 · Exercise / conversion · Disposed 280 · Balance 0 F4: The shares underlying this stock option are fully vested and exercisable. |
| Common StockSEC Table I · non-derivative | IndirectBy SQN LLC | 655,540 |
Reported balance
Holding disclosure · report date 2026-01-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 655,540 F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 10, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $551.24 to $551.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4: The shares underlying this stock option are fully vested and exercisable.
Prelude Therapeutics Inc
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-08 | Direct | 38,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 38,000 · Balance 38,000 F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALEXION PHARMACEUTICALS, INC.
Report date July 21, 2021 · Filed July 23, 2021
Section 16 reporting ended · disclosed 2021-07-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-21 transaction · row 1
1 source rowRow 1 · 2021-07-21 · Disposition to issuer · Disposed 12,840 · Balance 0 F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Alexion common stock disposed in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 12, 2020, by and among Alexion and AstraZeneca PLC. In accordance with the Merger Agreement, upon the First Effective Time (as defined in the Merger Agreement), each share of Alexion common stock was converted into the right to receive (i) 2.1423 American Depositary Shares (ADSs) of AstraZeneca PLC and (ii) $60.00 in cash (the "Merger Consideration"). Upon the First Effective Time, 2,495 restricted stock units were fully vested and cancelled and converted into the right to receive the Merger Consideration with respect to each share of Alexion common stock subject to such restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 7,877 | $370.44 | $2,917,943.28 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 14 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 267,171 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $369.90 to $370.88, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 7,992 | $369.44 | $2,952,554.89 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 13 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 275,048 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $368.90 to $369.88, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,788 | $368.34 | $2,500,325.18 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 12 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 283,040 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.90 to $368.89, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 7,119 | $367.31 | $2,614,887.72 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 11 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 289,828 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.90 to $367.88, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,152 | $366.22 | $1,154,329.54 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 296,947 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.89 to $366.88, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,716 | $365.19 | $626,670.67 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 300,099 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.79 to $365.75, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,529 | $364.02 | $1,284,638.93 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,815 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.78 to $364.77, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,591 | $363.08 | $940,731.21 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 305,344 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.74 to $363.73, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,439 | $362.29 | $521,331.71 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,935 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.73 to $362.70, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,754 | $361.13 | $633,423.77 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,374 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.72 to $361.62, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,153 | $360.27 | $1,135,937.62 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 311,128 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.71 to $360.67, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 455 | $359.31 | $163,484.96 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,281 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.71 to $359.68, inclusive. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,600 | $358.23 | $573,171.04 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,736 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.70 to $358.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 13, 2025 Filed Aug 13, 2025 22:18 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 129,172 | $9.45 | $1,220,675.40 |
DisclosureSEC source: 0001236927-25-000007 · wk-form4_1755123534.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 43,605 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · derivative · entry 17 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,172 Underlying: Common Stock · 43,605 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 600 | $359.81 | $215,886.00 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 14 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.78 to $359.87, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,032 | $358.83 | $1,805,614.95 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 13 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,764 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.48 to $359.41, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 8,434 | $357.93 | $3,018,785.84 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 12 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,796 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.48 to $358.47, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,094 | $356.94 | $1,818,251.34 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 11 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,230 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.48 to $357.46, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,244 | $355.97 | $1,866,710.35 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 206,324 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.48 to $356.46, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,546 | $355.00 | $2,323,856.18 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,568 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.48 to $355.47, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 4,768 | $354.06 | $1,688,137.10 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 218,114 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.48 to $354.47, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,382 | $352.61 | $487,308.82 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 222,882 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.48 to $353.47, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,202 | $351.59 | $1,125,805.91 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,264 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.16 to $352.12, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 3,303 | $350.93 | $1,159,112.54 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 227,466 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.16 to $351.14, inclusive. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 43,605 | $9.45 | $412,067.25 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,203 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · derivative · entry 16 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 172,777 Underlying: Common Stock · 3,203 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 300 | $351.04 | $105,312.33 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.00 to $351.24, inclusive. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,903 | $350.19 | $1,016,604.76 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,464 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:45 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 3,203 | $9.45 | $30,268.35 |
DisclosureSEC source: 0001236927-25-000005 · wk-form4_1755121546.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:06 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,400 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001628280-25-035580 · wk-form4_1753218411.xml · derivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 175,980 Underlying: Common Stock · 1,400 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:06 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,400 | $350.03 | $490,043.96 |
DisclosureSEC source: 0001628280-25-035580 · wk-form4_1753218411.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 18, 2025 Filed Jul 22, 2025 21:06 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 1,400 | $9.45 | $13,230.00 |
DisclosureSEC source: 0001628280-25-035580 · wk-form4_1753218411.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,564 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · derivative · entry 14 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 177,380 Underlying: Common Stock · 2,700 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 700 | $351.57 | $246,098.02 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 11 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.17 to $352.00, inclusive. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,000 | $350.10 | $700,203.00 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 10 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,864 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.61, inclusive. Read SEC document |
| July 17, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 2,700 | $9.45 | $25,515.00 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 9 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,176 | $0.00 Strike: $9.45 | $0.00 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · derivative · entry 13 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,080 Underlying: Common Stock · 26,176 shares Expires 2026-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The shares underlying this stock option are fully vested and exercisable. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 1,200 | $356.62 | $427,941.24 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 8 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,164 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $356.18 to $357.00, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,784 | $355.61 | $2,056,859.81 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 7 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 188,364 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $355.13 to $356.11, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 6,851 | $354.65 | $2,429,696.87 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 6 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 194,148 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $354.13 to $355.12, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,319 | $353.82 | $820,506.72 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 5 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 200,999 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $353.12 to $354.08, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,110 | $352.67 | $744,133.07 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 4 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 203,318 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $352.09 to $352.98, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 2,371 | $351.38 | $833,130.52 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,428 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $351.01 to $352.00, inclusive. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | SaleCommon Stock | 5,541 | $350.17 | $1,940,274.79 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 2 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 207,799 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $350.00 to $350.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. Read SEC document |
| July 16, 2025 Filed Jul 18, 2025 20:13 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | Exercise / conversionCommon Stock | 26,176 | $9.45 | $247,363.20 |
DisclosureSEC source: 0001628280-25-035342 · wk-form4_1752869569.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 213,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,290 | $0.00 Strike: $285.73 | $0.00 |
DisclosureSEC source: 0001628280-25-032846 · wk-form4_1750797003.xml · derivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,290 Underlying: Common Stock · 1,290 shares Expires 2035-06-20 F3 · derivative.exercise_date: The option vests as to 100% of underlying shares on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided that the Reporting Person continues to serve as a director of the Issuer until such date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 20:30 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantCommon Stock | 715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-032846 · wk-form4_1750797003.xml · nonDerivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,164 F1 · kind: Represents a grant of restricted stock units, which vest on the date of the Issuer's annual meeting of stockholders to be held in 2026, provided the Reporting Person continues in service with the Issuer on such date. Read SEC document |
| June 12, 2025 Filed Jun 13, 2025 20:14 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantDirector Stock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001562180-25-004795 · primarydocument.xml · derivative · entry 1 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The option award will fully vest upon the earlier of (a) the Issuer's next annual stockholder meeting, or (b) the one-year anniversary of the grant date, such to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| June 25, 2024 Filed Jun 28, 2024 01:41 UTC | MADRIGAL PHARMACEUTICALS, INC. MDGL · Entity 3441 | GrantStock Option (Right to Buy) · Derivative | 1,105 | $0.00 Strike: $280.04 | $0.00 |
DisclosureSEC source: 0000950170-24-078748 · ownership.xml · derivative · entry 3 FRIEDMAN PAUL A · CIK 0001236927 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,105 Underlying: Common Stock · 1,105 shares Expires 2031-06-25 F3 · derivative.exercise_date: The option vests as to 100% of underlying shares on the first anniversary of the grant date, provided that the Reporting Person continues to serve as a director of the Issuer until such anniversary date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.